Document:

PHARM-OLAM

              International
                Ltd

            	
              CO#1
                

            
	 	 	 
	
              CHANGE
                ORDER FORM

            

    

     

    

      This
        Change Order 1 “CO1” is hereby incorporated into the terms and conditions of the
        Clinical Research Services Agreement dated 04 December 2005 (hereinafter
        referred to as the “Agreement”) by and between Pharm-Olam International (UK)
        Limited, (hereinafter referred to as “POI”) and Advaxis, Inc, (hereinafter
        referred to as “Client”).

      

      
        	
                Date:

              	
                13
                  December 2006

              	
                Change
                  Requested by:

              	
                Jelena
                  Tasic 

                (POI
                  Project Manager)

              
	
                Customer
                  Name:

              	
                Advaxis,
                  Inc.

              
	
                Customer
                  Address:

              	
                212
                  Carnegie Centre

                Suite
                  206 Priceton

                New
                  Jersey 08540

                USA

              
	
                Protocol
                  Title:

              	
                A
                  Phase 1 Open Dose Escalation Study to Determine the Safety and
                  Immunogenicity of Vaccination with Listeria
                  monocytogenes
                  expressing Human Papilloma Virus type 16 E7 (Lovaxin-C) for the
                  Treatment
                  of Progressive, Recurrent and Advanced Squamous Cell Cancer of
                  the
                  Cervix

              
	
                Protocol
                  Number:

              	
                Lm-LLO-E7-01
                  (POI Study# 319)

              

      

      

      
        	
                Description
                  of Change Order

              
	
                 

                The
                  original contract was for 2 sites in Serbia and 1 in Mexico. The
                  actual
                  sites POI has are 1 site in Serbia and 2 in sites Mexico. In addition,
                  there have been 5 protocol amendments and one Investigator Brochure
                  update. In addition, the timelines have been extended by 4.5 months
                  with
                  the estimated completion date revised to 15 October 2006. The out
                  of scope
                  services associated with this change are described below:

                 

                1.  Identification
                  of 2 additional sites in Mexico

                2.  Protocol
                  Review for additional site in Mexico

                3.  Translations
                  of submission and approval documents and additional PIL 

                4.  Preparation
                  of Investigator Source Document Notebook

                5.  Review
                  of  AML lab manual (for the Israeli central lab)

                6.  Listeria
                  quantification procedure - preparation (review and amending of
                   procedure,  TC with microbiologists from Serbia and
                  Israel)

                7.  HPV
                  and Flow cytometry procedure - preparation 

                8.  PM
                  time for original SEVs reduced from 3 days to 2 days 

                9.  2
                  SEVs for additional sites in Mexico

                10.  Reduction
                  in cost for initial SEVs due to change in responsibility
                  assumptions

                11.  Reduction
                  in costs for initial EC and MoH submissions due to change in
                  assumptions

                12.  Translations
                  and back translation of additional PIF

                13.  Regulatory
                  submission of 5 protocol amendments in 2 countries

                14.  EC
                  submissions of 5 protocol amendments at 3 study sites

                15.  Translations
                  of approvals for 5 amendments

                16.  Initial
                  EC submissions for additional sites

                17.  MoH
                  submission for additional sites

                18.  Import
                  licenses for additional sites

                19.  Monitoring
                  guidelines writing

                20.  Reduction
                  in Investigator/Hospital contracts due to a change in
                  assumptions

                21.  Insurance
                  negotiation and agreement

                22.  First
                  drug re-labeling at all sites

                23.  Second
                  drug re-labeling at all sites

                24.  CRA
                  and CTA time included for attendance at weekly teleconferences
                  with
                  Sponsor for 11 months 

              

      

       

      
        
          
            Effective
              01 February 2006

          

        

        
          Page
            1 of
            3

          
            

          

        

        
          
          

        

      

      

        
          	
                  

                	
                  PHARM-OLAM

                  International
                    Ltd

                	
                  CO#1
                    

                
	 	 	 
	
                  CHANGE
                    ORDER FORM

                

        

         

      

      
        	
                
                  25.  SAE
                    narrative preparation and CIOMS form preparation for 10 SAEs

                  26.  Project
                    management time increased from 1 to 1.5 days per week for the
                    first 48
                    weeks and the additional 6 months extended study duration

                  27.  Medical
                    Writing - five amendments to the protocol

                  28.  Medical
                    Writing - one IB update

                  29.  Writing
                    of drug re-allocation
                    procedure

                

              

      

    

     

    
      Study
        Timelines:

      

      
        	
                Event

              	
                Date

              
	
                POI
                  Study Start Date

              	
                Completed
                  Aug 2005

              
	
                Protocol
                  Completion and Investigator Brochure

              	
                Completed
                  Oct 2005

              
	
                Submitting
                  Request for Special Protocol Assessment Meeting with FDA

              	
                Completed
                  Aug 2006 

              
	
                Special
                  Protocol Assessment Meeting with FDA

              	
                Completed
                  Aug 2006

              
	
                Submit
                  to Ethics Committee and Regulatory Authority, Mexico and
                  Serbia

              	
                Completed
                  Dec 2005

              
	
                Approval
                  Serbia

              	
                Completed
                  Feb 2006

              
	
                Approval
                  Mexico

              	
                Completed
                  Feb 2006

              
	
                First
                  Patient into Study, Serbia

              	
                Completed
                  16 March 2006

              
	
                Last
                  Patient into Study

              	
                01
                  May 2007

              
	
                Last
                  Patient out of Study

              	
                01
                  September 2007

              
	
                Close
                  Database

              	
                15
                  September 2007

              
	
                Statistical
                  Analysis Complete

              	
                30
                  September 2007

              
	
                Study
                  Draft Final Report

              	
                15
                  October 2007

              

      

      

      Estimated
        Costs:

      

      
        	
                Contract

              	
                Original

              	
                CO1

              	
                Revised
                  Total

              
	
                Price
                  (US$)

              	
                $430,000

              	
                $92,000

              	
                $522,000

              

      

    

     

    
      
        
          Effective
            01 February 2006

        

      

      
        Page
          2 of
          3

        
          

        

      

      
        
        

      

    

     

    

      
        	
                

              	
                PHARM-OLAM

                International
                  Ltd

              	
                CO#1
                  

              
	 	 	 
	
                CHANGE
                  ORDER FORM

              

      

       

    

    
      Payment
        Schedule:

      

      Reimbursement
        for the POI services outlined in this Project Change Order will be paid to
        POI
        according to the following schedule:

      

      
        	
                Item
                  #

              	
                Milestone

              	
                %

              	
                Amount
                  in USD ($)

              
	
                1

              	
                At
                  execution of Clinical Research Services Agreement 

                (Already
                  Invoiced)

              	
                8.24

              	
                43,000

              
	
                2

              	
                Upon
                  Protocol and IB Completion 

                (Already
                  Invoiced)

              	
                8.24

              	
                43,000

              
	
                3

              	
                Upon
                  Minister of Health Approval in Both Countries 

                (Already
                  Invoiced)

              	
                12.36

              	
                64,500

              
	
                4

              	
                10
                  patients in

              	
                20.00

              	
                104,400

              
	
                5

              	
                Last
                  patient in

              	
                20.00

              	
                104,400

              
	
                6

              	
                Last
                  patient out

              	
                15.58

              	
                81,350

              
	
                7

              	
                Signed
                  final report

              	
                15.58

              	
                81,350

              
	 	
                Total

              	
                100

              	
                522,000

              

      

      

      

      POI
        shall
        submit invoices to the sponsor for each payment in accordance with the payment
        schedule outlined above. Pass-through expenses will be invoiced to the sponsor
        as made by POI. All other terms and conditions according to the Agreement
        shall
        remain in full force and effect.

      

      Sponsor
        hereby authorises commencement of the tasks set forth above according to
        the
        estimated costs and payment schedule stated above.

       

      
        	
                Pharm-Olam
                  International Ltd

              	 	
                Sponsor

              
	 	 	 
	
                Accepted
                  by:

              	 	 	
                Accepted
                  by:

              	 
	
                Name:

              	 	 	
                Name:

              	 
	
                Title:

              	 	 	
                Title:

              	 
	
                Date:

              	 	 	
                Date:

              	 

      

      

      
        
          
            Effective
              01 February 2006

          

        

        
          Page
            3 of
            3CLINICAL
      RESEARCH SERVICES AGREEMENT

     

    BETWEEN

     

    ADVAXIS,
      INC

     

    AND

     

    APOTHECARIES
      LIMITED.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    TABLE
      OF CONTENTS

    
      	
              RECITALS

            	2
	 	 
	
              1.

            	
              DEFINITIONS

            	
              2

            
	 	 	 
	
              2.

            	
              INTERPRETATION

            	
              6

            
	 	 	 
	
              3.

            	
              APPOINTMENT
                & RELATIONSHIP OF PARTIES

            	
              6

            
	 	 	 
	
              4.

            	
              REPRESENTATIONS
                & WARRANTIES

            	
              7

            
	 	 	 
	
              5.

            	
              APOTHECARIES’
                OBLIGATIONS

            	
              7

            
	 	 	 
	
              6.

            	
              THE
                COMPANY’s OBLIGATIONS

            	
              9

            
	 	 	 
	
              7.
                

            	
              CRO
                COMPENSATION

            	
              10

            
	 	 	 
	
              8.

            	
              INSURANCE

            	
              11

            
	 	 	 
	
              9.

            	
              CONFIDENTIALITY

            	
              11

            
	 	 	 
	
              10.

            	
              INTELLECTUAL
                PROPERTY

            	
              12

            
	 	 	 
	
              11.

            	
              ARBITRATION

            	12
	 	 	 
	
              12.

            	
              NON-SOLICITATION
                OF STAFF

            	
              13

            
	 	 	 
	
              13.

            	
              TERM
                & TERMINATION

            	
              13

            
	 	 	 
	
              14

            	
              CONSEQUENCES
                OF TERMINATION

            	
              15

            
	 	 	 
	
              15.

            	
              GENERAL
                PROVISIONS

            	
              16

            
	 	 	 
	
              16.

            	
              APPLICABLE
                LAW

            	
              18

            

    

    

    
      	
              Attachment
                I and IA 

            	
              Payment
                Schedule, Budget, pass through and Timelines Schedule

            
	 	 
	
              Attachment
                II 

            	
              APOTHECARIES
                Clinical Research Services and APOTHECARIES
                deliverables

            
	 	 
	
              Attachment
                III 

            	
              Protocol
                and Schedule of Procedures

            

    

     

    

      
 

    

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          1 of
          23

        
          

        

      

      
        
        

      

    

    

This
      Clinical Research Services Agreement (this Agreement) is made and entered into
      effective as of 28 Oct. 2006, by and between Advaxis, Inc. (hereafter “THE
      COMPANY”), a Delaware Company with its principal office at 675 Route 1, North
      Brunswick, New Jersey 08902, and APOTHECARIES LIMITED. (hereafter “APOTHECARIES
”), a corporation organized under the laws of India, with its principal office
      at 579, Devli, East Sainik Farms, New Delhi 110062, India. 

     

    RECITALS

    

    WHEREAS,
      THE COMPANY is a biotech company that develops biological vaccines to cure
      cancer; and

    

    WHEREAS,
      APOTHECARIES is a contract research organization that plans, implements, and
      manages clinical trials; and

    

    WHEREAS,
      THE COMPANY desires to engage APOTHECARIES to assist THE COMPANY in planning,
      implementing, and managing regulatory and conduct of a phase I clinical trial
      on
      an Investigational Biological Product Lovaxin C, as hereafter defined;
      and

    

    WHEREAS,
      APOTHECARIES is willing to accept such engagement on the terms and conditions
      set forth herein;

    

    NOW,
      THEREFORE, in consideration of the premises and the mutual covenants and
      obligations set forth herein, and for other good and valuable consideration,
      the
      receipt and sufficiency of which are acknowledged, the parties agree as
      follows:

    

    
 

    
      	1.	DEFINITIONS

      	 	 

      	 	
              For
                purposes of this Agreement and the Protocol Synopsis, each capitalized
                term shall have the meaning ascribed to it in this Agreement. Each
                capitalized term not defined in this Agreement shall have the meaning
                ascribed to that term in the Protocol. In the event of a discrepancy
                in
                the meaning ascribed to a term in the body of this Agreement and
                the
                meaning ascribed to that term in the Protocol, the definition utilized
                in
                the body of this Agreement shall
                control.

            

    

    

    
      	
              1.1

            	
              “Case
                Report Form” or “CRF” means the record of pertinent information collected
                on each subject who participates in the
                Study;

            

    

     

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          2 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              1.2

            	
              “Clinical
                Laboratory Agreement” means the Agreement between THE COMPANY and the
                clinical laboratory or laboratories that will provide clinical laboratory
                services for the Study. 

            

    

    

    
      	
              1.3

            	
              “Clinical
                Research Associate” or “CRA” means the person assigned by APOTHECARIES to
                monitor one or more Study Sites. 

            

    

    

    
      	
              1.4

            	
              “Clinical
                Trial Agreement” means the agreement between APOTHECARIES and an
                Investigator that details the respective rights and obligations of
                both
                parties in relation to the Study;

            

    

    

    
      	
              1.5

            	
              “Clinical
                Trial Materials” means the Investigational Product, printed Case Report
                Forms, competitor substances, CRF monitoring conventions, the Protocol,
                the investigational drug brochure, informed consent form, guidelines
                for
                use of the Investigational Product, and all other materials provided
                by
                THE COMPANY to conduct the Study.

            

    

    

    
      	
              1.6

            	
              “Closeout
                Services” means those services described in Section 14 to be performed by
                APOTHECARIES upon termination of this Agreement. 

            

    

    

    
      	
              1.7

            	
              “Company
                Obligations” means the obligations of THE COMPANY under this
                Agreement.

            

    

    

    
      	
              1.8

            	
              “Confidential
                Information” means any information, whether written or oral, including all
                notes, studies, customer lists, forms, business or management methods,
                marketing data, fee schedules, or trade secrets of any member of
                the
                APOTHECARIES Group or of THE COMPANY, as appropriate, disclosed or
                otherwise made available to one party by the other party pursuant
                to this
                Agreement. Confidential Information shall also include the terms
                and
                provisions of this Agreement and any transaction or documents executed
                by
                the parties pursuant to this Agreement.
                In
                addition, Confidential Information shall include any data or information
                developed or generated in the course of performance of this Agreement.
                Publication of the fact that THE COMPANY and APOTHECARIES have entered
                into a clinical trials agreement, without disclosing the terms and
                provisions of this Agreement, shall not be construed as unauthorized
                disclosure of Confidential
                Information.

            

    

    

    
      	 	
              Confidential
                Information does not include any information that (i) is or becomes
                generally available to and known by the public, other than as a result
                of
                an unauthorized disclosure directly or indirectly by the receiving
                party
                or its affiliates, advisors, or representatives; (ii) is or becomes
                available to the receiving party on a non-confidential basis from
                a source
                other than the furnishing party or its affiliates, advisors, or
                representatives, provided that such source is not and was not bound
                by a
                confidentiality agreement with or other obligation of secrecy to
                the
                furnishing party of which the receiving party has knowledge at the
                time of
                such disclosure; or (iii) has already been or is hereafter independently
                developed by the receiving party by persons not having access to
                the
                Confidential Information of the furnishing party.
                

            

      	 	 

    

    
      	 	The parties acknowledge that they have already executed
              a
              confidentiality agreement. (“CDA”) In the event of a conflict or a
              contradiction between this Agreement and the CDA, the terms of the
              CDA
              shall control.

    

     

    
 

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          3 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              1.9

            	
              “CRO
                Compensation” means the compensation to be paid by THE COMPANY to
                APOTHECARIES as set out in Attachment
                1.

            

    

    

    
      	
              1.10

            	
              “Effective
                Date” means the effective date of this Agreement as set forth in the
                initial paragraph of this
                Agreement.

            

    

    

    
      	
              1.11

            	
              “Food
                and Drug Administration” means the United States government agency
                responsible for ensuring compliance with the Food, Drug, and Cosmetics
                Act
                of 1938.

            

    

    

    
      	
              1.12

            	
              “Force
                Majeure Event” means an event beyond the reasonable control of the
                relevant party including, but not limited to, acts of God, a public
                enemy,
                or a civil or military authority; fires or other catastrophes; strikes,
                lockouts, or other industrial action taken by the employees of any
                party
                or any third party; delays in transportation; riots; or invasions,
                wars,
                or threats of war. 

            

    

    

    
      	
              1.13

            	
              “Good
                Clinical Practice” means the clinical standards established by the FDA,
                counterpart agencies of each country in which the Study will take
                place,
                and ICH treaties designed to regulate the activities of THE COMPANY’s
                investigators, monitors, and Institutional Review Boards (“IRBs”) involved
                in clinical drug testing. 

            

    

    

    
      	
              1.14

            	
              “Institutional
                Review Board” means the independent group of professionals designated to
                ensure that the Study is safe and effective for human participation
                and
                that the Study adheres to the regulations issued by the FDA
                and any other applicable country-specific laws, regulations or
                guidelines.

            

    

    

    
      	
              1.15

            	
              “Investigational
                New Drug Application” or “IND” means the petition filed by THE COMPANY
                with the FDA requesting the FDA to allow human testing on the
                Investigational Product. 

            

    

     

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          4 of
          23

        
          

        

      

      
        
        

      

    

    
 

    
      	
              1.16

            	
              “Investigational
                Product” means the product (drug, device, or biologic) described in the
                Protocol that will be evaluated in this
                Study.

            

    

    

    
      	
              1.17

            	
              “Investigator”
                means an
                individual who actually conducts a clinical investigation, i.e.,
                under
                whose immediate direction the Investigational Product is administered
                or
                dispensed to, or used involving a subject, or, in the event of an
                investigation conducted by a team of individuals, is the responsible
                leader of that team.

            

    

    

    
      	
              1.18

            	
              “APOTHECARIES
                Group” means the following persons and entities, as constituted at the
                date of this Agreement or subsequently: (i) APOTHECARIES; and (ii)
                any
                person or entity that directly, or indirectly through one or more
                intermediaries, controls, is controlled by, or is under common control
                with APOTHECARIES.
                For the purpose of this definition, Investigators identified and
                deployed
                by Apothecaries shall be treated as Contractors of
                Apothecaries.

            

    

    

    
      	
              1.19

            	
              “APOTHECARIES’
                Obligations” means the obligations of APOTHECARIES under this
                Agreement. 

            

    

    

    
      	
              1.20

            	
              “Project
                Manager” means the manager assigned by APOTHECARIES to be the primary
                contact person between APOTHECARIES and THE COMPANY during the
                Study. 

            

      	 	 

      	1.21	“Protocol”
              means the plan that describes the objectives, study design, and
              methodology and any approved amendments thereto, which is attached
              as
              Attachment
              III,
              and which is herein incorporated by
              reference.

    

     

    
      	
              1.22

            	
              “Regulatory
                Requirements” means those laws, regulations, and professional and ethical
                standards and guidelines then in effect in the countries in which
                the
                Study is conducted that apply to the Investigational Product or clinical
                trials in general.

            

    

    

    
      	
              1.23

            	
              “Related
                Products” means any product (drug, device, or biologic), other than the
                Investigational Product, administered or utilized as part of this
                Study.

            

    

    

    
      	
              1.24

            	
              “Serious
                Adverse Event” shall take the meaning given this term in the
                Protocol.

            

    

    

    
      	
              1.25

            	
              “Services”
                means the services to be furnished by APOTHECARIES in connection
                with the
                Study as set out in this Agreement and the list of deliverable specified
                in Attachment
                II.

            

    

    

    
      	
              1.26

            	
              “Staff”
                means the staff assigned to the Study by THE COMPANY either directly
                or
                indirectly through the Clinical Trial
                Agreement.

            

    

     

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          5 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              1.27

            	
              “Standard
                Operating Procedures” or “SOP’s” means internal procedures for the
                management of a clinical trial designed to ensure that the trial
                is
                carried out in a consistent, controlled, and effective
                manner.

            

    

    

    
      	
              1.28

            	
              “Study”
                means the clinical trial of the Investigational Product, the details
                of
                which are set out in the Attachments I, II and III and the
                Protocol.. 

            

    

    

    
      	
              1.29

            	
              “Study
                Documents” means the documents produced by APOTHECARIES in connection with
                the Study that are, in the sole discretion of APOTHECARIES, necessary
                for
                the production of the Final Study Report. 

            

    

    

    
      	
              1.30

            	
              “Term”
                means the duration of this Agreement as set out in Section
                13.

            

    

    

    
      	
              2.

            	
              INTERPRETATION

            

    

    

    
      	
              2.1

            	
              Words
                of any gender used in this Agreement shall be held and construed
                to
                include any other gender, and words in the singular number shall
                be held
                to include the plural, and the plural to include the singular, unless
                the
                context requires otherwise.

            

    

    

    
      	
              2.2

            	
              The
                headings of the sections of this Agreement are inserted for convenience
                only and in no way define, limit, or prescribe the intent of this
                Agreement.

            

    

    

    
      	
              2.3

            	
              Unless
                otherwise specified, references in this Agreement to Sections and
                Attachment I are to the sections of, and Attachment I to, this Agreement.
                Attachment I is deemed to be
                incorporated into, and form part of, this Agreement, and the term
                “Agreement” shall be construed accordingly. 

            

    

    

    
      	
              2.4

            	
              Unless
                otherwise specified, any reference to a statute, rule, or regulation
                shall
                be to that statute, rule, or regulation as amended from time to
                time.

            

    

    

    
      	
              3.

            	
              APPOINTMENT
                AND RELATIONSHIP OF PARTIES

            

    

    

    
      	
              3.1

            	
              THE
                COMPANY hereby engages the services of APOTHECARIES, and APOTHECARIES
                accepts such engagement, to perform the Study and the Services, under
                the
                terms and conditions contained in this
                Agreement.

            

    

    

    
      	
              3.2

            	
              During
                the Term, APOTHECARIES shall at all times be the independent contractor
                of
                THE COMPANY, and nothing in this Agreement is intended, nor shall
                be
                construed, to create between THE COMPANY and APOTHECARIES the relationship
                of principal and agent, employer and employee, partnership, or joint
                venture, and the parties shall not represent themselves
                otherwise.

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          6 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              3.3

            	
              THE
                COMPANY shall be liable for its own debts, obligations, acts or omissions,
                including but not limited to the payment of all required compensation,
                withholding, social security and other taxes or benefits for THE
                COMPANY’s
                employees. Likewise, APOTHECARIES shall be liable for its own debts,
                obligations, acts or omissions, including but not limited to the
                payment
                of all required compensation, withholding, social security and other
                taxes
                or benefits for APOTHECARIES’ employees. 

            

    

    

    
      	
              3.4

            	
              If
                the Internal Revenue Service or any other government authority shall,
                at
                any time, question or challenge the independent contractor status
                of
                APOTHECARIES, upon receipt by either party of notice from the Internal
                Revenue Service or any other governmental authority, the receiving
                party
                shall promptly notify the other party and afford the other party
                the
                opportunity to participate in any discussion or negotiation with
                the
                Internal Revenue Service or other government authority, regardless
                as to
                who initiates such discussions or negotiations. 

            

    

    

    
      	
              4.

            	
              REPRESENTATIONS
                AND WARRANTIES

            

    

    

    
      	
              4.1

            	
              APOTHECARIES
                warrants to THE COMPANY that it has the authority to enter into this
                Agreement.

            

    

    

    
      	
              4.2

            	
              THE
                COMPANY warrants to APOTHECARIES that (i) it has the authority to
                enter
                into this Agreement; and (ii) all consents and approvals required
                for the
                Study (except for the consent of the individuals who will participate
                in
                the Study) have been, or will be obtained prior to initiation of
                the
                Study.

            

    

    

    
      	
              5.

            	
              APOTHECARIES’
                OBLIGATIONS

            

    

    

    
      	 	
              In
                addition to APOTHECARIES’s Obligations set forth in Attachment I and II
                and elsewhere in this Agreement, APOTHECARIES shall have the following
                obligations:

            

    

    

    
      	
              5.1

            	
              Before
                commencement of the Study, APOTHECARIES shall assign to the Study
                a
                Project Manager and sufficient personnel, including CRAs, with suitable
                experience and training to fulfill APOTHECARIES’ obligations under this
                Agreement.
                Any change in the Project Manager thereafter must be reasonably acceptable
                to THE COMPANY.

            

    

    

    
      	
              5.2

            	
              APOTHECARIES
                shall apply to the Study systems of quality control designed to ensure
                that, as far as is reasonably practicable, THE COMPANY and the
                Investigators conduct the Study; generate data; and record and report
                data, all in compliance with the Regulatory Requirements, Good Clinical
                Practice, the Protocol, and this Agreement, in that
                order.

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          7 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              5.3

            	
              APOTHECARIES
                shall use its best efforts to perform the Services and deliverables
                within
                the time frames specified in Attachment
                I.

            

    

    

    
      	
              5.4

            	
              APOTHECARIES
                shall procure and maintain consents, approvals, licenses, and operating
                certificates as required.

            

    

    

    
      	
              5.5

            	
              APOTHECARIES
                shall retain all material Study Documents, as determined by APOTHECARIES
                in its sole discretion, until this Agreement has terminated and all
                Closeout Services has been performed. All
                Study Documents and relevant copies of CRF pages will be forwarded
                to THE
                COMPANY after the Study is completed. CRF pages containing personal
                information of patients shall not be forwarded to the
                Company.

            

    

    

    
      	
              5.6

            	
              Company
                shall have the right to visit and co-monitor a Study Site or inspect
                and
                audit any of the Study Documents maintained by APOTHECARIES. All
                such
                visits and inspections must be conducted during normal working hours
                on
                regular business days, unless otherwise agreed. APOTHECARIES
                shall arrange access to the Study Site as soon as reasonably practicable
                following notification by THE
                COMPANY.

            

    

    

    
      	
              5.7

            	
              APOTHECARIES
                will provide THE COMPANY with written status reports in accordance
                with
                either THE COMPANY or APOTHECARIES
                SOPs.

            

    

    

    
      	
              5.8

            	
              APOTHECARIES
                shall notify THE COMPANY by phone immediately after becoming aware
                of a
                Serious Adverse Event and shall submit an initial written report
                to THE
                COMPANY regarding that Serious Adverse Event via facsimile within
                24 hours
                after APOTHECARIES becomes aware of any such event, and shall file
                the
                appropriate documentation as required under local statutes in a timely
                manner. 

            

    

    

    
      	
              5.9

            	
              APOTHECARIES
                shall indemnify and save harmless THE COMPANY, its officers, agents,
                and
                employees from all suits, actions, losses, damages, claims, or liability
                of any character, types, or description, including without limiting
                the
                generality of the foregoing, all expenses of litigation, court costs,
                and
                reasonable attorney’s fees for injury or death to any person, or injury to
                property, received or sustained by any person or persons or property,
                arising out of, or occasioned by APOTHECARIES (or its agents or
                employees), in connection with its execution or performance of this
                Agreement. The Investigators are not and shall not be deemed the
                agents of
                APOTHECARIES for purposes of this Section 5.9. THE COMPANY will notify
                APOTHECARIES of any claim or suit which may be subject to the provisions
                of this Section 5.9 as soon as reasonably practicable after receiving
                notice of the claim. APOTHECARIES shall have the sole right to control
                and
                settle any such claim or suits, and THE COMPANY shall make all reasonable
                efforts to cooperate (at APOTHECARIES’ expense) as requested by
                APOTHECARIES in handling any such claim or
                suit.

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          8 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              5.10

            	
              For
                the removal of any doubt, subject to the Company providing APOTHECARIES
                with the materials necessary for APOTHECARIES to complete and write
                the
                Investigational Product, APOTHECARIES shall be responsible to obtain
                all
                approvals, construct all the necessary written materials submit any
                and
                all applications as necessary, and cause the Phase I clinical trial
                to be
                conducted and completed in accordance with the Protocol (a draft
                of which
                is attached hereto as Attachment
                III)
                and in a form and manner acceptable to the US Food and Drug
                Administration.

            

    

    

    
      	
              5.11

            	
              APOTHECARIES
                shall follow the Special Protocol Assessment procedure of the US
                Food and
                Drug Administration and seek the feedback or approval of the US Food
                and
                Drug Administration to the
                Protocol.

            

    

    

    
      	
              5.12

            	
              Outside
                regulatory consultant:
                APOTHECARIES may work with a third party regulatory consultant pre
                approved by THE COMPANY.

            

    

    

    
      	
              5.13

            	
              APOTHECARIES
                shall be responsible for the list of services and deliverables specified
                in Attachment
                II.
                APOTHECARIES as the contracted research organization agrees to conduct
                the
                proposed phase trial for Advaxis with the highest quality of care
                and in
                compliance with accepted standards of Good Research Practice and
                Good
                Laboratory Practice. Without derogating from the generality of the
                foregoing statement, the standards of management mentioned in Attachment
                II shall
                apply.

            

    

    

    
      	
              5.14

            	
              APOTHECARIES
                understands that as the aforementioned clinical trial is ongoing
                and
                coordinated through a central site in Belgrade Serbia. Apothecaries
                agrees
                to collaborate with this site, adhere to all appropriate monitoring
                and
                other SOPs, including monitoring, remote data entry, and all necessary
                forms completion and
                communications.

            

    

    

    
      	
              6.

            	
              THE
                COMPANY’S OBLIGATIONS

            

    

    

    
      	 	
              In
                addition to THE COMPANY’s Obligations set forth in the Attachment I and
                elsewhere in this Agreement, THE COMPANY shall have the following
                obligations:

            

    

    
    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          9 of
          23

        
          

        

      

      
        
        

      

    

     

    
      	
              6.1

            	
              THE
                COMPANY shall provide APOTHECARIES, at no expense to APOTHECARIES
                (i) with
                all information and documentation reasonably necessary for APOTHECARIES
                to
                perform its duties hereunder, including but not limited to, all Clinical
                Trial Materials; and (ii) with all advice, guidance, and assistance
                reasonably requested by APOTHECARIES to fulfill its duties under
                this
                Agreement.

            

    

     

    
      	
              6.2

            	
              Except
                for the APOTHECARIES obligations in Paragraph 5.4, or as otherwise
                specifically provided herein, THE COMPANY shall procure and maintain
                all
                consents, approvals, licenses, and operating certificates required
                to
                conduct the Study. THE COMPANY shall also develop, comply with, and
                require Staff to comply with, policies and procedures designed to
                assure,
                at all times, that such consents, approvals, licenses, and operating
                certificates remain in effect throughout the
                Term.

            

    

    

    
      	
              6.3

            	
              THE
                COMPANY shall indemnify and save harmless APOTHECARIES, its officers,
                agents, and employees from all suits, actions, losses, damages, claims,
                or
                liability of any character, types, or description, including without
                limiting the generality of the foregoing, all expenses of litigation,
                court costs, and attorneys’ fees for injury or death to any person, or
                injury to property, received or sustained by any person or persons
                or
                property, arising out of, or occasioned by the Investigational Product
                or
                the acts or omissions of the Staff or THE COMPANY (or its agents
                or
                employees), in connection with the Study or their execution or performance
                of this Agreement. APOTHECARIES will notify THE COMPANY of any claim
                or
                suit which may be subject to the provisions of this Section 6.3 as
                soon as
                reasonably practicable after receiving notice of the claim. THE COMPANY
                shall have the sole right to control and settle any such claims or
                suits,
                and APOTHECARIES shall make all reasonable efforts to cooperate (at
                THE
                COMPANY’s expense) as requested by THE COMPANY in handling any such claim
                or suit.

            

    

    

    
      	
              7.

            	
              CRO
                COMPENSATION

            

    

    

    
      	
              7.1

            	
              THE
                COMPANY shall pay APOTHECARIES the amounts set forth in Attachment
                I
                for all services provided and expenses incurred by APOTHECARIES pursuant
                to this Agreement, according to the payment schedule set forth in
                Attachment I. Upon early termination of this Agreement pursuant to
                Sections 13.2, 13.3, or 13.4, THE COMPANY shall continue to pay
                APOTHECARIES the amounts set forth in Attachment I for all services
                provided by APOTHECARIES prior to the termination of this Agreement
                and
                for the Closeout Services furnished by APOTHECARIES after the termination
                of this Agreement, provided that in no event will the amount owed
                to
                APOTHECARIES exceed the maximum amounts specified in Attachment
                I.

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          10
          of 23

        
          

        

      

      
        
        

      

    

     

    
      	
              7.2

            	
              APOTHECARIES
                shall submit invoices to THE COMPANY upon the completion of each
                payment
                milestone event set forth in Attachment I. THE COMPANY shall make
                full
                payment of such sums by electronic transfer to such bank account
                in the
                India as APOTHECARIES may reasonably specify from time to time, upon
                receipt of invoice (“Due Date”), without any deduction, set off or
                withholding except any tax which THE COMPANY is required by law to
                deduct
                or withhold. Any amounts which remain unpaid for thirty (30) days
                or more
                after the Due Date shall bear interest at the rate equal to 6% per
                annum.
                Interest shall be computed on the basis of a 365 or 366-day year,
                as the
                case may be, subject to the provisions hereof limiting interest to
                the
                maximum rate of interest allowed by applicable law.
                If
                any amounts remain unpaid for Thirty (30) days or more after the
                Due Date,
                APOTHECARIES shall have the right to discontinue all work and services
                under this Agreement until such amounts are paid in
                full.

            

    

    

    
      	
              7.3

            	
              If
                THE COMPANY is required by law to make any tax deduction or withholding,
                THE COMPANY shall provide reasonable assistance as requested by
                APOTHECARIES to assist APOTHECARIES to claim exemption from, or if
                that is
                not possible a credit for, the deduction or withholding under any
                applicable double taxation or similar agreement. THE COMPANY shall
                also
                supply APOTHECARIES from time to time with proper evidence as to
                the
                deduction or withholding and payment over of the tax deducted or
                withheld. 

            

    

    

    
      	
              8.

            	
              INSURANCE

            

    

    

    
      	
              8.1

            	
              THE
                COMPANY and APOTHECARIES shall each maintain, at its sole cost and
                expense, insurance coverage with a reputable insurer (which shall
                be
                either occurrence based or claims made coverage) in an amount usual
                and
                customary for companies engaged in activities as contemplated by
                this
                Agreement. All such insurance shall be in place before the first
                patient
                is enrolled in the Study. Each shall designate the other party as
                an
                additional named insured on all such policies, and an endorsement
                shall be
                made on each such policy prohibiting the insurer from canceling the
                policy
                for any reason or substantially modifying its terms without first
                giving
                the other party at least twenty-eight (28) days written notice of
                its
                intention to do so.

            

    

    

    
      	
              8.2

            	
              Upon
                request by either party, the other party shall provide evidence of
                that
                party’s compliance with this Section.

            

    

    

    
      	
              9.

            	
              CONFIDENTIALITY

            

    

    

    
      	
              9.1

            	
              Except
                as specified in the following Section, each of the parties agrees
                (i) that
                it shall not disclose any Confidential Information of the other party
                to
                other persons without the express written authorization of the other
                party; (ii) that such Confidential Information shall not be used
                in any
                way detrimental to the other party; and (iii) that the parties will
                keep
                such Confidential Information confidential and will ensure that its
                affiliates and advisors who have access to such Confidential Information
                comply with these non-disclosure obligations. 

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          11
          of 23

        
          

        

      

      
        
        

      

    

     

    
      	
              9.2

            	
              Notwithstanding
                the foregoing, the parties may disclose Confidential Information
                to (i)
                those of its representatives, including, but not limited to the other
                party’s legal, financial and accounting advisors, who need to know
                Confidential Information for the purpose of conducting this Study,
                it
                being understood and agreed by the parties that such representatives
                will
                be informed of the confidential nature of the Confidential Information,
                will agree to be bound by this Section, and will be directed by the
                respective party not to disclose to any other person any Confidential
                Information; and (ii) the FDA, an IRB, or comparable governmental
                or
                professional body with jurisdiction over the Study provided such
                disclosure is requested by the respective governmental or professional
                body or is required in order to satisfy Section 6.1. 

            

    

    

    
      	 	
              In
                the event that either party determines that it is required by law
                to
                disclose the other party’s Confidential Information, or such disclosure is
                in response to a subpoena or a similar legal process, such disclosure
                shall be permitted provided that the other party required to make
                such
                disclosure promptly notifies the other party and assists the other
                party
                in obtaining a protective order or other appropriate
                remedy.

            

    

    

    
      	
              10.

            	
              INTELLECTUAL
                PROPERTY

            

    

    

    
      	
              10.1

            	
              APOTHECARIES
                acknowledge that, as between THE COMPANY and APOTHECARIES, any and
                all
                intellectual property rights that may arise in the Study itself shall
                belong solely to THE COMPANY, including without limitation all data
                generated in the course of the Study, and all Clinical Trial
                Materials.

            

    

    

    
      	
              10.2

            	
              THE
                COMPANY acknowledges that, as between APOTHECARIES and THE COMPANY,
                any
                and all intellectual property rights in works authored by APOTHECARIES
                before the Effective Date of this Agreement and works authored by
                APOTHECARIES independent of the Study shall belong to
                APOTHECARIES.

            

    

    

    
      	
              11.

            	
              ARBITRATION

            

    

    

    
      	
              11.1

            	
              Any
                controversy or claim between the parties arising out of or relating
                to
                this Agreement, shall be finally determined and settled pursuant
                to
                arbitration in Princeton, NJ, by one arbitrator whom (i) shall have
                at
                least 5 years of experience as an arbitrator and (ii) shall be associated
                with the American Health Lawyers Association ADR Service or the American
                Arbitration Association. .

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          12
          of 23

        
          

        

      

      
        
        

      

    

     

    
      	
              11.2

            	
              The
                arbitration proceedings shall be conducted in accordance with the
                Commercial Arbitration Rules of the American Arbitration Association.
                A
                determination, award, or other action shall be considered the valid
                action
                of the arbitrators if supported by the affirmative vote of two or
                three of
                the three arbitrators. The costs of arbitration (exclusive of a party’s
                own costs incurred in attending the arbitration, and of the fees
                and
                expenses of legal counsel to such party, all of which shall be borne
                by
                such party) shall, in the discretion of the arbitrators, be ordered
                to be
                paid by the one or both of the parties either equally or in such
                proportions as may be decided by the arbitrators. The arbitration
                award
                shall be final and binding, and judgment upon such award may be entered
                in
                any court having jurisdiction. Notwithstanding any
                other provision hereof, no party shall be awarded punitive or exemplary
                damages in any arbitration
                hereunder.

            

    

    

    
      	
              12.

            	
              NON-SOLICITATION
                OF STAFF

            

    

    

    
      	 	
              During
                the term of this Agreement and for a period of thirty-six months
                following
                its termination or expiration, THE COMPANY shall not directly or
                indirectly (i) solicit or entice any employee or contractor of
                APOTHECARIES with whom it comes into contact as a result of participation
                in the Study, to be employed by it or any other person or entity;
                or (ii)
                approach any such employee or contractor for such purpose or authorize
                or
                approve the taking of such action by any other
                person.

            

      	 	 

    

    
      	
              13.

            	
              TERM
                AND TERMINATION

            

    

    

    
      	
              13.1

            	
              This
                Agreement shall commence on the Effective Date and, unless terminated
                pursuant to this Section 13, shall
                continue until such time as the Services and Closeout Services have
                been
                completed.

            

    

    

    
      	
              13.2

            	
              This
                Agreement may be terminated upon the mutual, written consent of both
                parties.
                This Agreement may also be terminated by THE COMPANY without cause
                upon
                thirty (30) days prior written notice to the other
                party.

            

    

    

    
      	
              13.3

            	
              Either
                party may immediately terminate this Agreement for cause, upon written
                notice to the other party stating the date of termination, pursuant
                to the
                following:

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          13
          of 23

        
          

        

      

      
        
        

      

    

     

    
      	 	
              13.3.1

            	
              Termination
                by APOTHECARIES. APOTHECARIES
                may terminate this Agreement for cause upon the occurrence of any
                of the
                following events:

            

    

    

    
      	 	
              (i)

            	
              THE
                COMPANY fails to maintain the insurance coverage required by Section
                8.1;

            

    

    

    
      	 	
              (ii)

            	
              The
                FDA, IRB, or any regulatory authority with jurisdiction over the
                Study
                suspends or revokes any consent, approval, license, or operating
                certificate required to conduct the
                Study;

            

    

    

    
      	 	
              (iii)

            	
              If
                on behalf of the COMPANY, APOTHECARIES
                enters into a Clinical Trial Agreement with an Investigator relating
                to
                the Study, and the Investigator or any member of the Investigator’s staff
                fails to possess all qualifications, training, and licenses necessary
                to
                perform the duties and obligations of that individual under that
                agreement
                or fails in any material manner to abide by the provisions of the
                Regulatory Requirements or this Agreement; provided, however, that
                THE
                COMPANY may cure any such deficiency by removing the affected individual
                from providing services under this
                Agreement;

            

    

    

    
      	 	
              (iv)

            	
              THE
                COMPANY breaches any material provision of this Agreement, other
                than
                those specifically referenced in this Section 13.3.1, and fails to
                remedy
                that breach within 30 days after receiving notice of such breach;
                or

            

    

    

    
      	 	
              (v)

            	
              THE
                COMPANY files a petition for the appointment of a receiver in liquidation
                or a trustee with respect to itself or any of its property; or any
                person
                other than THE COMPANY files a petition for the appointment of a
                receiver
                in liquidation or a trustee with respect to THE COMPANY in bankruptcy,
                insolvency, or reorganization, compromise, adjustment or other relief
                relating to the relief of debtors, and such involuntary petition
                is not
                vacated or set aside or stayed within 60 days from THE COMPANY’s receiving
                notice of such petition.

            

    

    

    
      	 	
              13.3.2

            	
              Termination
                by THE COMPANY. THE
                COMPANY may terminate this Agreement for cause upon the occurrence
                of any
                of the following events:

            

    

    

    
      	 	
              (i)

            	
              The
                FDA, IRB, or any regulatory authority with jurisdiction over the
                Study
                suspends or revokes any consent, approval, license, or operating
                certificate required to conduct the
                Study;

            

    

    
      	 	 	 

    

    
    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          14
          of 23

        
          

        

      

      
        
        

      

    

     

    
      	 	
              (ii)

            	
              The
                occurrence of a Serious Adverse Event which should cause the Study
                to be
                terminated due to safety concerns

            

    

    

    
      	 	
              (iii)

            	
              APOTHECARIES
                breaches any material provision of this Agreement, other than those
                specifically referred to in this Section 13.3.2, and fails to remedy
                that
                breach within 30 days after receiving notice of such breach;
                or

            

    

    

    
      	 	
              (iv)

            	
              APOTHECARIES
                files a petition for the appointment of a receiver in liquidation
                or a
                trustee with respect to itself or any of its property; any entity
                APOTHECARIES controls makes a voluntary assignment for the benefit
                of
                creditors or files a petition in bankruptcy or insolvency or for
                reorganization, compromise, adjustment, or other relief; or if any
                person
                other than APOTHECARIES files a petition for the appointment of a
                receiver
                in liquidation or a trustee with respect to APOTHECARIES or any entity
                it
                controls in bankruptcy, insolvency, or reorganization, compromise,
                adjustment or other relief relating to the relief of debtors, and
                such
                involuntary petition is not vacated or set aside or stayed within
                60 days
                from APOTHECARIES ’s receiving notice of the petition.
                

            

    

    

    
      	
              13.4

            	
              In
                the event of any change or reinterpretation of a Regulatory Requirement,
                the adoption of any new law or regulation, or the initiation of an
                enforcement action with response to laws, regulations, or guidelines
                applicable to this Agreement, any of which shall affect the legality
                of
                this Agreement, the parties agree to negotiate in good faith to amend
                this
                Agreement to comply with the offended law or regulation. If the parties
                do
                not agree to such amendment within 30 days prior to the effective
                date of
                the offended law or regulation (or such earlier time as may be required
                to
                comply), then either party may terminate this Agreement immediately
                by
                giving written notice to such effect to the other
                party.

            

    

    

    
      	
              14.

            	
              CONSEQUENCES
                OF TERMINATION

            

    

    

    
      	
              14.1

            	
              The
                termination of this Agreement for any reason shall not affect any
                right or
                remedy existing hereunder prior to the effective date of
                termination.

            

    

    

    
      	
              14.2

            	
              Without
                limiting the foregoing, upon termination of this Agreement, THE COMPANY
                shall, in addition to all CRO Compensation then due, compensate
                APOTHECARIES as specified in Attachment I, for all Closeout Services
                required to terminate and closeout the Study, including but not limited
                to, any activities necessary to satisfy the requirements of any
                governmental, regulatory, or professional authority with jurisdiction
                over
                the Study

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          15
          of 23

        
          

        

      

      
        
        

      

    

     

    
      	
              15.

            	
              GENERAL
                PROVISIONS

            

    

    

    
      	
              15.1

            	
              This
                Agreement sets forth the entire agreement and understanding among
                the
                parties as to the matters contained therein, and merges and supersedes
                any
                prior discussions, agreements, and understanding of every kind and
                nature
                relating thereto.

            

    

    

    
      	
              15.2

            	
              Any
                amendment of or modification to this Agreement shall become effective
                only
                if it is in writing and executed by the
                parties.

            

    

    

    
      	
              15.3

            	
              This
                Agreement shall be binding upon, and inure to the benefit of, the
                parties
                and their respective legal representatives, trustees, receivers,
                successors and permitted assigns.

            

    

    

    
      	
              15.4

            	
              Except
                as otherwise specified in this Agreement or otherwise agreed to by
                the
                parties in writing, all notices, requests, demands, and other
                communications provided for in this Agreement shall be in writing
                in
                English and shall be deemed to have been given at the time when personally
                delivered, or mailed by registered or certified mail, return receipt
                requested, to the address of the other party stated below or to such
                other
                address as any such party may have fixed by notice, provided, however,
                that any notice of change of address shall be effective only upon
                receipt
                by addressee. 

            

    

    

    All
      notices to THE COMPANY shall be addressed to:

    

    Dr.
      John
      Rothman, VP Clinical Development

    Advaxis
      Inc., USA

    675,
      Route 1, North Brunswick,

    NJ
      08902,
      USA

    

    If
      notices or communications by telephone or facsimile are 

    specifically
      authorized in this Agreement or otherwise agreed to by 

    the
      parties in writing, calls to THE COMPANY shall be placed and 

    facsimiles
      to THE COMPANY shall be sent to the following numbers:

    Phone:
      732 545 1590 Fax: 801 459 3596.

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          16
          of 23

        
          

        

      

      
        
        

      

    

     

    All
      notices to APOTHECARIES shall be addressed to:

     

    Apothecaries
      Limited

    579,
      Devli, East Sainik Farms, New Delhi 110062, India

    Email:
      Madhulika@Apothecaries.net

    Phones:
      +91-98114 99712, +91-98114 99114

    

    If
      notices or communications by telephone or facsimile are 

    specifically
      authorized in this Agreement or otherwise agreed to by 

    the
      parties in writing, calls to APOTHECARIES shall be placed and 

    facsimiles
      to APOTHECARIES shall be sent to the following numbers:

    Phone:
      +91-11-2450 2451/52/53 

    Fax:
      +91-11-29912416

    

    The
      parties shall give notice to each other of any change of their address or
      telephone, facsimile, or similar number at the earliest possible
      opportunity.

     

    
      	
              15.5

            	
              All
                agreements of the parties, as well as any rights or benefits accruing
                to
                them, pertaining to a period of time following the termination or
                expiration of this Agreement or any of its provisions, including
                but not
                limited to

              Paragraph
                6.3, and Sections 7 through 12, and 14, shall survive such termination
                or
                expiration hereof and shall not be
                merged.

            

      	 	 

      	15.6	The
              waiver by any party of a breach or default by any other party shall
              not
              operate as a waiver of a continuing or subsequent breach or default
              of the
              same or a different nature or kind. 

      	 	 

      	15.7	If
              any provision of this Agreement or the application of any such provision
              to any person or circumstance is held invalid, the remainder of this
              Agreement and the application of such provision to other persons or
              circumstances shall not be affected unless the invalid provision
              substantially impairs the benefits of the remaining provisions of this
              Agreement.

      	 	 

      	15.8	No
              party may assign this Agreement or its rights and duties hereunder,
              without the prior written consent of the other party,
              except that THE COMPANY may assign this Agreement to a purchaser or
              acquirer of substantially all of the business to which this Agreement
              relates. Apothecaries, may, however assign certain site management
              related
              tasks to the CRCs retained by Clinical Research Academy, New Delhi,
              India.
              Apothecaries will be entirely responsible for the conduct and management
              of all such CRCs / staff members.

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          17
          of 23

        
          

        

      

      
        
        

      

    

     

    
      
        	15.9	The
                provisions of this Agreement shall be self-executing and shall not
                require
                further agreement by the parties except as may otherwise be specifically
                provided in this Agreement; provided, however, that, at the request
                of a
                party, the other party shall execute such additional instruments
                and
                perform such additional acts as may be reasonably necessary to effectuate
                this Agreement.

        	 	 

        	15.10	This Agreement may be executed in counterpart
                originals,
                with each counterpart to be deemed an original, but all counterparts
                together shall constitute a single instrument. 

        	 	 

        	15.11	In
                the event that performance by a party of any of its obligations under
                the
                terms of this Agreement shall be interrupted or delayed by a Force
                Majeure, that party shall be excused from such performance for the
                same
                amount of time as such occurrence shall have lasted or such period
                of time
                as is reasonably necessary after such occurrence abates for the effects
                thereof to have dissipated.

        	 	 

        	16.	APPLICABLE LAW

        	 	 

        	 	This
                Agreement shall be governed by and be construed under the laws of
                the New
                Delhi India, without giving effect to its choice-of-law rules, and
                exclusive venue of any action or other proceeding that may be brought
                or
                arise out of, in connection with, or by reason of this Agreement
                shall be
                in India..

        	 	 

      

       

    

    
      IN
        WITNESS WHEREOF, this Agreement is executed by the parties hereto and is
        effective as of the day and year first above written.

Advaxis,
      Inc.

    

    By: ____________________________________

    

    Apothecaries
      Limited

     

    By: ____________________________________

     

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          18
          of 23

        
          

        

      

      
        
        

      

    

    

    Attachment
      I

     

    Timelines
      and Payment Schedule

    Timelines:

     

    
      	
              Event

            	
              Date
                

            
	 	 
	
              Contract
                and transfer of funds

            	
              Day
                0

            
	 	 
	
              Site
                Assessment for 6-8 sites

            	
              Day
                30

            
	
              Site
                Feasibility Reports

            	
              Day
                30

            
	
              List
                of probable investigator sites and investigators

            	
              Day
                30

            
	
              Estimated
                enrolment rates

            	
              Day
                45

            
	 	 
	
              Preparation
                of regulatory dossiers for 

            	 
	
              conducting
                clinical trials on Lovaxin C

            	
              Day
                30

            
	 	 
	
              Submission
                to Indian Regulatory Authorities

            	
              Day
                40

            
	 	 
	
              Obtaining
                regulatory approvals in India (likely)

            	
              Day
                130-160

            
	 	 
	
              First
                patient in to study India

            	
              Day
                145-175

            
	
              Last
                patient in to study India

            	
              To
                be decided 

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          19
          of 23

        
          

        

      

      
        
        

      

    

    

    Payment
      Schedule for Services:

    

    
      	
              Execution
                of Clinical Research Services Agreement, and initiation of compilation
                of
                dossier for Indian regulatory submission

            	 	
              $

            	
              6,500

            	 
	
              Site
                assessment report - first 4 sites

            	 	
              $

            	
              1,500

            	 
	
              Each
                additional site assessment report

            	 	
              $

            	
              1,500

            	 
	
              Submission
                for regulatory approval in India

            	 	
              $

            	
              4,000

            	 
	
              Upon
                obtaining regulatory approval in India

            	 	
              $

            	
              6,500

            	 
	
              Upon
                enrollment of each qualified patient 

              (institutional
                cost)

            	 	
              $

            	
              1,500

            	 
	
              Upon
                enrollment of each qualified patient 

              (management
                cost)

            	 	
              $

            	
              750

            	 
	
              Upon
                completion of each qualified patient 

              (institutional
                cost)

            	 	
              $

            	
              3500

            	 
	
              Upon
                completion of each qualified patient 

              (management
                cost)

            	 	
              $

            	
              750

            	 
	
              Completion
                of report for India patients (per patient)

            	 	
              $

            	
              1,000

            	 

    

    

    All
      the
      following expenses are included in the above cost:

    Administrative
      cost (telephones, faxes, mail, etc)

    Site
      visits as follows: monthly and as required to comply with safety review panel
      meetings, site initiation and closing, and in the event of reportable adverse
      events.

    CRF
      preparation and printing

    Investigator
      fees estimated from protocol synopsis

    Above
      costs are based on INR-US$ conversion rate of 46 INR = 1US$. Any fluctuations
      in
      the conversion rate shall be to the Sponsor’s account.

    Service
      tax, if and when chargeable according to Govt. of India rules, shall be payable
      by the clients over and above the indicated costs. At present, service tax
      is
      not applicable to overseas clients who do not have their offices in India.
      However, for those overseas clients who have established an office in India
      the
      service tax may be chargeable @ 12.24% even if the assignment is carried out
      for
      the overseas office of the client.

    

    Pass-throughs:

     

    Invoices
      will be sent to Advaxis, Inc for all pass-through cost.

    The
      parties agree that the pass-through costs shall not exceed the cost structure
      detailed in Attachment
      IA:

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          20
          of 23

        
          

        

      

      
        
        

      

    

     

    Attachment
      IA

    
      	
              Pass-throughs

            
	 	 	 
	
              Item

            	
              Cost
                ($)

            	
              Notes

            
	
              Plasma
                sample shipment for titers 

            	
              To
                be decided 

            	 
	
              Import/Export
                Fees 

            	
              To
                be decided 

            	
              Vaccine
                shipment into India & samples for assay to Serbia

            
	
              Medical
                Insurance

            	
              To
                be decided

            	 
	
              Laboratory
                expenses

            	 	 
	
              EC
                Fees

            	 	 

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          21
          of 23

        
          

        

      

      
        
        

      

    

    

    Attachment
      II

    Clinical
      Research Services and APOTHECARIES’s deliverables

    

    APOTHECARIES
      Deliverables

     

    
      	 	
              1.

            	
              Protocol,
                Investigators Brochure and CRF
                translations

            

    

     

    
      	 	
              2.

            	
              Provide
                site assessment reports, 8 sites

            

    

     

    
      	 	
              3.

            	
              Submit
                to Ethics Committee and RA, India

            

    

     

    
      	 	
              4.

            	
              Obtain
                Approval for Phase I in Lovaxin C in
                India

            

    

     

    
      	 	
              5.

            	
              Recruit
                6-8 Phase I study sites In India

            

    

     

    
      	 	
              6.

            	
              Remote
                data entry into Advaxis existing study database and all necessary
                collaboration.

            

    

     

    
      	 	
              7.

            	
              Management
                and reporting of all adverse experiences Grade 3 or
                higher

            

    

    

    Quality
      of Study Management

    

    
      	 	
              1.

            	
              A
                site screening visit that assures each site has the appropriate facilities
                and personnel to conduct the proposed study. This includes approved
                and
                certified physicians, a dedicated study nurse, and adequate clerical
                personnel necessary facilities for patient visits, diagnostic devices,
                and
                so forth.

            

    

    

    
      	 	
              2.

            	
              A
                study initiation visit for previously screened sites in which the
                specific
                details of the protocol are reviewed in detail and instruction is
                given to
                the site personnel as to the correct methods for conducting the study.
                Specific attention is paid to following the study plan and schedule,
                collecting information, completing case report forms (CRF) and assuring
                their veracity when compared with the patient
                charts.

            

    

    

    
      	 	
              3.

            	
              A
                monitoring schedule which assures that CRFs are audited on a timely
                basis.
                Weekly calls with the sponsor to the site to track patient enrollment
                and
                visits at least once per month to assure adequate patient enrollment,
                enrolled patients are being treated in compliance with the protocol
                as
                written, auditing of CRF against original documents (patient charts,
                scans, X-rays, lab reports, etc). The retrieval of all CRF, or portions
                of
                CRF, which are completed, audited, and ready for data
                entry.

            

    

    

    
      	 	
              4.

            	
              Verification
                of data entered into the analytic database against the CRF data forms
                to
                assure the reliability of the data to be
                analyzed.

            

    

     

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          22
          of 23

        
          

        

      

      
        
        

      

    

    

    

    Attachment
      III

    Protocol

    

    

    
      
        
          Advaxis
            Clinical Research Agreement

          October
            18, 2006

        

      

      
        Page
          23
          of 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]